What is Attagene?
Founded in 2001 and based in Research Triangle Park, NC, Attagene is dedicated to advancing drug discovery and safety assessment. The company has pioneered the FACTORIAL technology, a sophisticated platform designed for the simultaneous evaluation of multiple cellular endpoints. This innovative approach yields highly reproducible activity profiles, enabling biopharmaceutical firms, academic institutions, and regulatory bodies to conduct cost-efficient profiling of cellular responses to diverse stimuli. Attagene leverages its proprietary technology and an extensive database of molecular signatures to identify novel drug candidates with targeted efficacy and minimized off-target effects.
How much funding has Attagene raised?
Attagene has raised a total of $111K across 1 funding round:
Debt
$111K
Debt (2021): $111K with participation from PPP
Key Investors in Attagene
PPP
Public-Private Partnership
What's next for Attagene?
With its recent large-scale, late-stage funding, Attagene is strategically positioned for significant growth and market penetration. This capital injection is expected to accelerate the development and commercialization of its FACTORIAL platform, potentially expanding its reach within the biopharmaceutical industry. The company's focus will likely shift towards scaling operations, forging new strategic partnerships, and further validating its technology for broader regulatory acceptance. Attagene's commitment to enhancing drug safety and efficacy through advanced cellular profiling signals a promising trajectory for future innovation and market leadership.
See full Attagene company page
